Results 11 to 20 of about 6,178 (191)
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome [PDF]
Anais Brasileiros de Dermatologia, 2017 Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in ...
Asude Kara Polat +3 more
doaj +3 more sources
Signs of deferasirox genotoxicity [PDF]
Cytotechnology, 2013 Iron overload is a major health problem for patients who have to have continuous blood transfusions. It brings some metabolic problems together. Various iron chelating agents are being used for treatment of hemochromatosis which arises from excess iron accumulation.
Ila, Hasan Basri +3 more
core +6 more sources
Cancer Medicine, 2019 Deferasirox is an oral iron‐chelating agent having possible antileukemia and immune modulatory effects. Few reports have evaluated deferasirox in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the impact of
Yoo Jin Kim, Ki-Seong Eom, Chang-Ki Min
exaly +2 more sources
Ocular Complications in Patients With Transfusion‐Dependent Beta‐Thalassemia Receiving Deferasirox: A Cross‐Sectional Study [PDF]
Health Science ReportsBackground and Aims Transfusion‐dependent beta‐thalassemia is a chronic hematologic disorder necessitating lifelong blood transfusions and iron chelation therapy, which can lead to systemic and ocular complications.
Abdolreza Medghalchi +7 more
doaj +2 more sources
Deferasirox: appraisal of safety and efficacy in long-term therapy
Journal of Blood Medicine, 2013 Preeti Chaudhary, Vinod PullarkatJane Ann Nohl Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles, CA, USAAbstract: Deferasirox is a once-daily, oral iron chelator that is widely used in the management of ...
Chaudhary P, Pullarkat V
doaj +1 more source
Deferasirox, an oral chelator in the treatment of iron overload [PDF]
Italian Journal of Medicine, 2013 BACKGROUND Deferasirox is a once-daily oral iron chelator developed for treating iron overload complicating long-term transfusion therapy in patients with diseases such as beta-thalassemia and myelodysplastic syndromes. Iron overload can damage the liver,
I. Portioli
doaj +2 more sources
Therapeutics and Clinical Risk Management, 2016 Anna W Chalmers, Jamile M Shammo Department of Internal Medicine, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA Abstract: Transfusion-dependent anemia is a common feature in a wide array of hematological disorders ...
Chalmers AW, Shammo JM
doaj +1 more source
Therapeutics and Clinical Risk Management, 2018 Carmen Fucile,1 Francesca Mattioli,1 Valeria Marini,1 Massimo Gregori,2 Aurelio Sonzogni,3 Antonietta Martelli,1 Natalia Maximova4 1Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy; 2Department of Pediatric Radiology, Institute for ...
Fucile C +6 more
doaj +2 more sources
Update on the use of deferasirox in the management of iron overload
Therapeutics and Clinical Risk Management, 2009 Ali Taher,1 Maria Domenica Cappellini21American University of Beirut, Beirut, Lebanon; 2Universitá di Milano, Policlinico Foundation IRCCS, Milan, ItalyAbstract: Regular blood transfusions as supportive care for patients with chronic anemia ...
Ali Taher, Maria Domenica Cappellini
doaj +1 more source
The Possible Protective Role of Vitamin E Against Deferasirox-Induced Injury of Renal Cortical Tubules in Adult Male Albino Rat: A Histological and Immunohistochemical Study [PDF]
The Egyptian Journal of Histology, 2023 Introduction: Deferasirox, as an oral iron chelator, is presently the first-choice medication for iron overload caused by repeated blood transfusions due to its ease of use, efficacy, and high bioavailability, yet deferasirox has been also reported with ...
Shimaa Badr +2 more
doaj +1 more source